Abstract
Alzheimers disease (AD) is characterized by the presence, in the brain of the patients, of two aberrant structures: intracellular neurofibrillary tangles (NFTs), containing an abnormal hyperphosphorylated form of tau protein, and extracellular senile plaques (SPs), mainly composed by fibrillar amyloid β peptide. Another feature of AD is the neurodegeneration and dysfunction of basal forebrain cholinergic system. A possible connection among those AD characteristics could occur. Thus, the purpose of this short review is to summarize the involvement of nicotinic (nAChR) and muscarinic (mAChR) receptors on tau phosphorylation, in a direct way, or through the previous interaction of some of these receptors with amyloid β. Several studies have demonstrated that nAChR activation results in a significantly increase of tau phosphorylation, whereas mAChR activation, may prevent tau phosphorylation.
Keywords: Alzheimer's disease, tau phosphorylation, amyloid b peptide, nicotinic receptors, muscarinic receptors, acetylcholine
Current Molecular Medicine
Title: Acetylcholine Receptors and Tau Phosphorylation
Volume: 6 Issue: 4
Author(s): A. Rubio, M. Pérez and Jesus Ávila
Affiliation:
Keywords: Alzheimer's disease, tau phosphorylation, amyloid b peptide, nicotinic receptors, muscarinic receptors, acetylcholine
Abstract: Alzheimers disease (AD) is characterized by the presence, in the brain of the patients, of two aberrant structures: intracellular neurofibrillary tangles (NFTs), containing an abnormal hyperphosphorylated form of tau protein, and extracellular senile plaques (SPs), mainly composed by fibrillar amyloid β peptide. Another feature of AD is the neurodegeneration and dysfunction of basal forebrain cholinergic system. A possible connection among those AD characteristics could occur. Thus, the purpose of this short review is to summarize the involvement of nicotinic (nAChR) and muscarinic (mAChR) receptors on tau phosphorylation, in a direct way, or through the previous interaction of some of these receptors with amyloid β. Several studies have demonstrated that nAChR activation results in a significantly increase of tau phosphorylation, whereas mAChR activation, may prevent tau phosphorylation.
Export Options
About this article
Cite this article as:
Rubio A., Pérez M. and Ávila Jesus, Acetylcholine Receptors and Tau Phosphorylation, Current Molecular Medicine 2006; 6 (4) . https://dx.doi.org/10.2174/156652406777435444
DOI https://dx.doi.org/10.2174/156652406777435444 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry Silencing of Disease-related Genes by Small Interfering RNAs
Current Molecular Medicine Prospects for Rational Development of Pharmacological Gap Junction Channel Blockers
Current Drug Targets New Generation of Oncolytic Herpes Virus
Current Cancer Therapy Reviews Prion Disease: Chemotherapeutic Strategies
Infectious Disorders - Drug Targets The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies
Anti-Cancer Agents in Medicinal Chemistry Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective
Current Alzheimer Research Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Role of Genomics-Based Strategies in Overcoming Chemotherapeutic Resistance
Current Pharmaceutical Biotechnology Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets Proteasome Structure, Function, and Lessons Learned from Beta-Lactone Inhibitors
Current Topics in Medicinal Chemistry Sulfation of Phenylephrine by the Human Cytosolic Sulfotransferases
Drug Metabolism Letters Polyphenols as Potential Inhibitors of Amyloid Aggregation and Toxicity:Possible Significance to Alzheimers Disease
Mini-Reviews in Medicinal Chemistry Subject Index to Volume 3
Current Drug Targets - CNS & Neurological Disorders Ellipticines as DNA-Targeted Chemotherapeutics
Current Medicinal Chemistry Flavonoids as Sirtuin Modulators
Current Topics in Medicinal Chemistry Telomere Shortening Is a Sole Mechanism of Aging in Mammals
Current Aging Science Regulation of Transcription Factors by Heterotrimeric G Proteins
Current Molecular Pharmacology Cerebral Arachidonate Cascade in Dementia: Alzheimers Disease and Vascular Dementia
Current Neuropharmacology